

Ocular Hypertension Treatment Study (OHTS)

Current as of: 10/27/17

<https://ohts.wustl.edu>

1. Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group: [The Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants](#). Arch Ophthalmol 1999; 117:573-83. [PMID: 10326953](#).
2. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Study Group. [Confirmation of Visual Field Abnormalities in the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2000; 118:1187-94. [PMID: 10980763](#). [View PowerPoint Presentation](#).
3. Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. [Contralateral Effect of Topical \$\beta\$ -Adrenergic Antagonists in Initial One-eyed Trials in the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2000; 130:441-53. [PMID: 11024416](#).
4. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. [Central Corneal Thickness in the Ocular Hypertension Treatment Study \(OHTS\)](#). Ophthalmology 2001; 108:1779-88. [PMID: 11581049](#). [View PowerPoint Presentation](#).
5. Feuer WJ, Parrish RK, II, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: Reproducibility of Cup/Disk Ratio Measurements Over Time at an Optic Disc Reading Center](#). Am J Ophthalmol 2002; 133:19-28. [PMID: 11755836](#).
6. Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, and the Ocular Hypertension Study Group. [Baseline Visual Field Characteristics in the Ocular Hypertension Treatment Study](#). Ophthalmology 2002; 109:432-7. [PMID: 11874743](#).
7. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish, RK, Wilson MR, Gordon MO for the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma](#). Arch Ophthalmol 2002; 120:701-13. [PMID: 12049574](#). [View PowerPoint Presentation](#). [\[Editorial\]](#).
8. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma](#). Arch Ophthalmol 2002; 120:714-20. [PMID: 12049575](#).
9. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO for the Ocular Hypertension Study Group. [Classification of Visual Field Abnormalities in the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2003;121:643-50. [PMID: 12742841](#).
10. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA, for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. [Racial Differences in Optic Disc Topography: Baseline Results From the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2004; 122:22-8. [PMID: 14718290](#).

11. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA and the OHTS CSLO Ancillary Study Group. [The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study Design and Baseline Factors](#). Am J Ophthalmol 2004; 137:219-27. [PMID: 14962409](#). [View PowerPoint Presentation](#).
12. Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. [The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals](#). Arch Ophthalmol 2004; 122:813-20. [PMID: 15197055](#). [View PowerPoint Presentation](#).
13. Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study (OHTS). [Baseline Risk Factors for the Development of Primary Open-angle Glaucoma in the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2004; 138(4):684-5. [PMID: 15488816](#).
14. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. [Central Corneal Thickness and Measured IOP Response to Topical Ocular Hypotensive Medication in the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2004; 138:717-22. [PMID: 15531304](#).
15. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study (OHTS) Group. [Incorporating the Results of the Ocular Hypertension Treatment Study Into Clinical Practice. Letter to Editor](#). Arch Ophthalmol 2005; 123:1021-2. [PMID: 16009857](#).
16. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Group. [Baseline Topographic Optic Disc Measurements are Associated With the Development of Primary Open-Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2005; 123:1188-97. [PMID: 16157798](#). [View PowerPoint Presentation](#).
17. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group. [Normal Visual Field Test Results Following Glaucomatous Visual Field End Points in the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2005; 123:1201-6. [PMID: 16157799](#). [PMCID: PMC1828122](#).
18. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vandenbroucke R, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. [Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders](#). Am J Ophthalmol 2005; 140:762-4. [PMID: 16226544](#). [View PowerPoint Presentation](#).
19. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group (OHTS). [Management of Ocular Hypertension: A Cost-effectiveness Approach From the Ocular Hypertension Treatment Study](#). Am J Ophthalmol 2006; 141:997-1008. [PMID: 16765666](#). [PMCID: PMC1775049](#).
20. Herman DC, Hodge DO, Bourne, WM. [Changes in the Corneal Thickness in Patients With Treated and Untreated Ocular Hypertension](#). Cornea 2006; 25:639-43. [PMID: 17077653](#).
21. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension Treatment Study Group. [Asymmetries and Visual Field Summaries as Predictors of Glaucoma in the Ocular Hypertension Treatment Study](#). Invest Ophthalmol Vis Sci 2006; 47:3896-903. [PMID: 16936102](#). [PMCID: PMC1995656](#).

22. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish II RK, Kass MA, Gordon MO, Ocular Hypertension Treatment Study Group. [The Association between Glaucomatous Visual Fields and Optic Nerve Head Features in the Ocular Hypertension Treatment Study](#). *Ophthalmology* 2006; 113(9):1603-12. [PMID: 16949445](#). [PMCID : PMC1995656](#).
23. Baratz KH, Nau CB, Winter EJ, McLaren JW, Hodge DO, Herman DC, Bourne WM. [Effects of Glaucoma Medications on Corneal Endothelium, Keratocytes, and Subbasal Nerves Among Participants in the Ocular Hypertension Treatment Study](#). *Cornea* 2006; 25:1046-52. [PMID:17133051](#).
24. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group. [Topical Ocular Hypotensive Medication and Lens Opacification: Evidence From the Ocular Hypertension Treatment Study](#). *Am J Ophthalmol* 2006; 142:800-10. [PMID: 17056362](#). [PMCID: PMC1976472](#). [View PowerPoint Presentation](#).
25. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon MO, Kass MA, Ocular Hypertension Treatment Study Group. [Detection and Prognostic Significance of Optic Disc Hemorrhages During the Ocular Hypertension Treatment Study](#). *Ophthalmology* 2006; 113(12):2137-43. [PMID: 16996592](#). [PMCID: PMC1995568](#). [View PowerPoint Presentation](#).
26. Ocular Hypertension Treatment Study (OHTS) Group, European Glaucoma Prevention Study Group. [Validated Prediction Model for the Development of Primary Open-Angle Glaucoma in Individuals with Ocular Hypertension](#). *Ophthalmology* 2007; 114(1):10-9. [PMID: 17095090](#). [PMCID: PMC1995665](#). [View PowerPoint Presentation](#).
27. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. [Comparison of Initial Intraocular Pressure Response With Topical \$\beta\$ -Adrenergic Antagonists and Prostaglandin Analogues in African American and White Individuals in the Ocular Hypertension Treatment Study](#). *Archives of Ophthalmology* 2007; 125(4):454-9. [PMID: 17420364](#).
28. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. [Visual Field Quality Control in the Ocular Hypertension Treatment Study \(OHTS\)](#). *J Glaucoma* 2007; 16:665-9. [PMID: 18091452](#).
29. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. [Is a History of Diabetes Mellitus Protective Against Developing Primary Open-angle Glaucoma?](#) *Arch Ophthalmol* 2008; 126:280-2. [PMID: 18268230](#). [View PowerPoint Presentation](#).
30. Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. [Diabetes and Glaucoma](#). *Arch Ophthalmol* 2008;126(5):746-a-7. [PMID: 18474807](#).
31. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA, Ocular Hypertension Treatment Study Group. [Changes in Central Corneal Thickness over Time: The Ocular Hypertension Treatment Study](#). *Ophthalmology* 2008; 115:1550-6. [PMID: 18378313](#).
32. The Ocular Hypertension Treatment Group and the European Glaucoma Prevention Study Group. [The Accuracy and Clinical Application of Predictive Models for Primary Open-Angle Glaucoma in Ocular Hypertensive Individuals](#). *Ophthalmology* 2008; 115(11):2030-6. [PMID: 18801578](#). [PMCID: PMC3117658](#).
33. Bhorade AM, Gordon MO, Wilson B, Weinreb RN, Kass MA, for the Ocular Hypertension Treatment Study Group. [Variability of Intraocular Pressure Measurements in Observation Participants in the Ocular Hypertension Treatment Study](#). *Ophthalmology* 2009;116:717-24. [PMID: 19243824](#). [PMCID: PMC2790916](#). [View PowerPoint Presentation](#).

34. Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, for the Ocular Hypertension Treatment Study Group. [Delaying Treatment of Ocular Hypertension](#). Arch Ophthalmol 2010;128(3):276-87. [PMID: 20212196](#). [PMCID: PMC3966140](#). [View PowerPoint Presentation](#).
35. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. [The Incidence of Retinal Vein Occlusion in the Ocular Hypertension Treatment Study](#). Ophthalmology 2010;117(3):484-8. [PMID: 20031222](#). [PMCID: PMC3077045](#).
36. Kymes SM, Plotzke MR, Kass MA, Boland MV, Gordon MO. [Effect of Patient's Life Expectancy on the Cost-effectiveness of Treatment for Ocular Hypertension](#). Arch Ophthalmol 2010;128(5):613-8. [PMID: 20457984](#). [PMCID: PMC4010144](#).
37. Weinreb RN, Zangwill LM, Jain Sonia, Becerra LM, Dirkes Keri, Piltz-Seymour JR, Cioffi GA, Trick GL, Coleman AL, Brandt JD, Liebmann JM, Gordon MO, Kass MA, for the OHTS CSLO Ancillary Study Group. [Predicting the Onset of Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). Ophthalmology 2010;117(9):1674-83. [PMID: 20633931](#). [PMCID: PMC3938159](#).
38. Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT, Kass MA, for the Ocular Hypertension Treatment Study Group. [The Utility of the Monocular Trial: Data from the Ocular Hypertension Treatment Study](#). Ophthalmology 2010;117(11):2047-54. [PMID: 20619460](#). [PMCID: PMC2955184](#).
39. Artes PH, Chauhan BC, Keltner JL, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Group. [Longitudinal and Cross-sectional Analyses of Visual Field Progression in Participants of the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2010;128(12):1528-32. [PMID: 21149774](#). [PMCID: PMC3914151](#).
40. Gao F, Miller JP, Xiong C, Beiser JA, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. [A joint-modeling Approach to Assess the Impact of Biomarker Variability on the Risk of Developing Clinical Outcome](#). Statistical Methods & Applications 2011;20(1):83-100. [PMID: 21339862](#). [PMCID: PMC3039885](#).
41. Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA. [A joint Model for Prognostic Effect of Biomarker Variability on Outcomes: Long-term Intraocular Pressure \(IOP\) Fluctuation on the Risk of Developing Primary Open-Angle Glaucoma \(POAG\)](#). JP Journal of Biostatistics 2011 May 1;5(2) 73-96. [PMID: 22180704](#). [PMCID: PMC3237682](#).
42. Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA. [The 10-Year Incidence of Glaucoma Among Patients With Treated and Untreated Ocular Hypertensive](#). Arch Ophthalmol 2011;129(12):1630-1. [PMID: 22159688](#).
43. Demirel S, De Moraes CG, Gardiner SK, Liebmann JM, Cioffi GA, George R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study. [The Rate of Visual Field Change in the Ocular Hypertension Treatment Study](#). Invest Ophthalmol Vis Sci 2012;53(1)224-7. [PMID: 22159015](#). [PMCID: PMC3292359](#).
44. Brandt JD, Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA, for the Ocular Hypertension Treatment Study Group. [Adjusting Intraocular Pressure for Central Corneal Thickness Does Not Improve Prediction Models for Primary Open-Angle Glaucoma](#). Ophthalmology 2012;119(3):437-42. [PMID: 21705084](#). [PMCID: PMC3184359](#).

45. De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Effect of Treatment on the Rate of Visual Field Change in the Ocular Hypertension Treatment Study Observation Group](#). Invest Ophthalmol Vis Sci 2012;53:1704-9. PMID: 22395889. PMCID: PMC3342789.
46. Kymes SM, Lambert DL, Lee PP, Musch DC, Siegfried CJ, Kotak SV, Stwalley DL, Fain J, Johnson C, Gordon MO. [The Development of a Decision Analytic Model of Changes in Mean Deviation in People with Glaucoma](#). Ophthalmology 2012;119:1367-74. PMID: 22537616. PMCID: PMC3389134.
47. Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA, for the Ocular Hypertension Treatment Study Group. [Reduction in Intraocular Pressure after Cataract Extraction: The Ocular Hypertension Treatment Study](#). Ophthalmology 2012;119:1826-31. PMID: 22608478. PMCID: PMC3426647.
48. De Moraes CG, Demirel S, BScOptom, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study](#). Arch Ophthalmol 2012;130:1541-46. PMID: 22892940.
49. Gardiner SK, Demirel S, De Moraes CG, Liebmann JM, Cioffi, GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Series Length used during Trend Analysis Affects Sensitivity to Changes in Progression Rate in the Ocular Hypertension Treatment Study \(OHTS\)](#). Invest Ophthalmol Vis Sci. 2013;54(2): 1252–9. PMID 23349433. PMCID: PMC3597197.
50. Zangwill LM, Jain S, Dirkes K, He F, Medeiros FA, Trick GL, Brandt JD, Cioffi GA, Coleman AL, Liebmann JM, Piltz-Seymour JR, Gordon MO, Kass MA, Weinreb RN; Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. [The Rate of Structural Change: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study](#). Am J Ophthalmology 2013;155(6):971–82. PMID: 23497845.
51. Gardiner SK, Demirel S, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. [Seasonal Changes in Visual Field Sensitivity and Intraocular Pressure in the Ocular Hypertension Treatment Study](#). Ophthalmology 2013 Apr;120(4):724-30. PMID: 23357622. PMCID: PMC3618610.
52. Savatovsky E, Mwanza JC, Budenz DL, Feuer WJ, Vandenbroucke R, Schiffman JC, Anderson DR; Ocular Hypertension Treatment Study [Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment](#). Ophthalmology 2015 Jan;122(1):79-86. PMID: 25208858.

OHTS 3 Publications

53. Christopher M, Abramoff MD, Tang L, Gordon MO, Kass MA, Budenz DL, Fingert JH, Scheetz TE. [Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension](#). Invest Ophthalmol Vis Sci. 2015 Jul 1;56(8):4470-9. PMID: 26193923. PMCID: PMC4509059.
54. Feng Gao, J Philip Miller, Julia A Beiser, Chengjie Xiong, Mae O Gordon. [Predicting Clinical Binary Outcome Using Multivariate Longitudinal Data: Application to Patients with Newly Diagnosed Primary Open - Angle Glaucoma](#). J Biom Biostat 6:254. PMID: 26904374. PMCID: PMC4760987.
55. Scheetz TE, Faga B, Ortega L, et al. [Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study](#). Ophthalmology 2016;123(12):2527-36. PMID: 27707548. PMCID: PMC5121091.

56. Khawaja AP, Cooke Bailey JN, et al. [Assessing the Association of Mitochondrial Genetic Variation With Primary Open-Angle Glaucoma Using Gene-Set Analyses](#). *Invest Ophthalmol Vis Sci*. 2016 Sep; 57(11): 5046–5052. [PMID: 27661856](#). [PMCID: PMC5040191](#).
57. Bailey JN, Loomis SJ, et al. [Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open angle glaucoma](#). *Nat Genet*. 2016 Feb; 48(2): 189–194. [PMID: 26752265](#). [PMCID: PMC4731307](#).
58. Budenz DL, Huecker JB, Gedde SJ, Gordon M, Kass M, Ocular Hypertension Treatment Study. [Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study](#). *Am J Ophthalmol*. Feb 2017;174:126-133. [PMID: 27832941](#).
59. Jamie L Schaefer, Alissa M Meyer, Cooper D Rodgers, Nicole C Rosenberg, Anthony J Leoncavallo, Zachary L Lukowski, Anthony B Greer, Gina M Martorana, Baiming Zou, Jonathan J Shuster, L Jay Katz, Joel S Schuman, Michael A Kass, Mark B Sherwood. [Comparing glaucomatous disc change using stereo disc viewing and the MatchedFlicker programme in glaucoma experts and trainees](#). *Br J Ophthalmol*. 2017 [Epub ahead of print]. [PMID: 28814418](#).